EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Market News Wall Street was closed on Monday for Presidents’ Day. U.S. stocks ended mixed on Friday due to strong earnings and economic data. While the Nasdaq rose, the Dow and the S&P 500 fell. How ...